Statin use is associated with a reduced risk of hepatocellular carcinoma recurrence after initial liver resection

Yoshikuni Kawaguchi1, Yoshihiro Sakamoto1, Daisuke Ito1, Kyoji Ito1, Junichi Arita1, Nobuhisa Akamatsu1, Junichi Kaneko1, Kiyoshi Hasegawa1, Kyoji Moriya2, Norihiro Kokudo1,3,*

1 Hepato-Biliary-Pancreatic Surgery Division, Department of Surgery, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan; 2 Department of Infection Control and Prevention, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan; 3 National Center for Global Health and Medicine, Tokyo, Japan.

Summary

Effective adjuvant therapies have not been established for hepatocellular carcinoma (HCC). The study aimed to determine prognostic influence of statin against HCC recurrence after initial resection. From 2003 to 2013, 734 patients underwent initial HCC resection. Exposure to statins was defined as the use at the recommended daily dosage for > 90 days after surgery. Outcomes were compared between patients who did and did not receive statins. Of 734 patients, 31 (4.2%) received statins for dyslipidemia (statin group) and 703 (95.8%) did not (non-statin group). The proportions of hepatitis B (6.5% vs. 22.8%, \( P = 0.032 \)), C (19.4% vs. 45.0%, \( P = 0.005 \)), and a fibrosis score of F3-4 (16.1% vs. 39.8%, \( P = 0.008 \)) were significantly lower in the statin than non-statin group. The recurrence-free survival rate was significantly higher in the statin than non-statin group (\( P < 0.001 \)), without significant difference of the overall survival rate (\( P = 0.142 \)). A multivariable Cox proportional hazards model revealed that the use of statins (hazard ratio, 0.34; \( P = 0.005 \)) was associated with a significantly lower risk of HCC recurrence. After one-to-two propensity score matching, the RFS rate was also significantly higher in the statin group \( (n = 31) \) than in the non-statin group \( (n = 62) \) (\( P = 0.008 \)). In conclusion: The statins use reduced the risk of HCC recurrence after initial resection. Statins may have protective influences on HCC recurrence in patients who undergo initial liver resection.

Keywords: Statin, liver resection, hepatocellular carcinoma

1. Introduction

Hepatocellular carcinoma (HCC) is the fifth most common cancer worldwide and the second among causes of cancer-related deaths among men, whereas among women, it is the seventh most common cancer and the sixth leading cause of cancer death (1). Liver resection remains the optimal treatment for HCC. Previously reported overall survival rates are 40% to 80% at 3 years and 20% to 70% at 5 years after HCC resection (2-4). Cumulative recurrence rates remain high (50-60% at 3 years and 70-100% at 5 years) (2-6). Adjuvant therapy has been expected to reduce HCC recurrence and prolong postsurgical survival. Indeed, several drugs including interferon, sorafenib, and acyclic retinoid have been examined to determine their protective effect against HCC recurrence (7-10). However, effective adjuvant therapies for use after HCC resection have yet to be established.

The protective effects of statins against the development of HCC were recently indicated in patients with hepatitis B (11-13) and hepatitis C (14,15), although conflicting results have also been reported (16). Use of nucleoside analogues, statins, and nonsteroidal anti-inflammatory drugs (NSAIDs)/
aspirin were reportedly associated with a reduced risk of HCC recurrence in patients with hepatitis B, who underwent liver resection (17). However, few studies have focused on the effectiveness of statin use against HCC recurrence after liver resection. We hypothesized that statin use can influence HCC recurrence after liver resection even in patients who receive statins on a daily basis for the treatment of dyslipidemia.

The aim of the present study was to determine the prognostic influence of statin use on initial liver resection of HCC by comparing long-term outcomes between patients who did and did not receive statins.

2. Methods

2.1. Study population

From January 2003 to December 2013, a total of 1,337 consecutive patients with HCC underwent liver resection at the University of Tokyo Hospital. The collected data were retrieved from prospectively maintained databases and included baseline patient characteristics such as specific drug use (statins), operative characteristics, histopathological data, and postoperative outcomes. Exposure to statins was defined as the use of statins at the recommended daily dosages for > 90 days after surgery. These recommended daily dosages were as follows: pravastatin, 10 mg/day; simvastatin, 5 mg/day; fluvastatin, 20 mg/day; pitavastatin, 1 mg/day; atorvastatin, 5 mg/day; and rosuvastain, 2.5 mg/day. Patients who underwent repeated hepatectomy (n = 603) were excluded from the present study. The remaining 734 patients were included in the analysis. This study was conducted with the approval of the Institutional Ethics Review Board of The University of Tokyo (ID: 2158-5). Written informed consent was obtained from all patients.

2.2. Surgical procedures and histopathological assessments

Chest and abdominal contrast-enhanced computed tomography, and ultrasonography were routinely performed before surgical resection. Additionally, magnetic resonance imaging with Gd-EOB-DTPA (Bayer Schering Pharma, Berlin, Germany) had been performed since 2007. Liver resection was indicated according to specific criteria based on preoperative liver function parameters, such as the presence/absence of uncontrolled ascites, serum bilirubin concentration, and indocyanine green retention rate at 15 min (ICG-R15). (18,19) Briefly, if the serum bilirubin concentration was normal, our criteria permitted right hepatectomy or trisectoriectomy when the ICG-R15 was < 10%, left hepatectomy or seectoriectomy when the ICG-R15 was < 20%, subsegmentectomy or monosegmentectomy when the ICG-R15 was < 30%, limited resection when the ICG-R15 was < 40%, and enucleation when the ICG-R15 was > 40%.

The histologic classification of tumors and the background liver was based on the system established by the Liver Cancer Study Group of Japan (20). The histologic differentiation of HCC (well, moderate, or poor) was determined according to the Edmondson grade (20,21). Both the fibrotic stage and the activity of hepatitis in the background liver were also recorded according to the classification proposed by Desmet et al. (22).

2.3. Postoperative management

Morbidity and mortality were defined as postoperative complications and death within 90 days after surgery, respectively. Postoperative morbidity was graded according to the Clavien-Dindo classification (23).

2.4. Patient follow-up

Measurement of blood tumor marker [alpha-fetoprotein (AFP) and des-γ-carboxyprothrombin (DCP)] were performed every month for six months after hospital discharge. Contrast-enhanced computed tomography or magnetic resonance imaging was performed every 3 to 4 months.

Recurrence was diagnosed as the appearance of a new lesion with radiographic features compatible with HCC. Recurrence-free survival (RFS) was defined as the interval between the operation and the date of diagnosis of the first recurrence, and overall survival (OS) was calculated based on the time from surgery to death or last follow-up.

2.5. Statistical analysis

Categorical variables are expressed as numerical figures (%), and were compared between groups using Fisher's exact test or the chi-square test as appropriate. Continuous variables are expressed as median (interquartile range, IQR) and were compared using the Wilcoxon's rank-sum test. OS and RFS curves were constructed using the Kaplan-Meier method and compared using the log-rank test. Factors with a P value of < 0.10 in a Cox proportional hazard model under univariable analysis were considered potential risk factors and were further analyzed in a multivariable Cox model. Hazard ratios (HRs) and 95% confidence intervals (CIs) were calculated for each factor. Based on previously reported evidence, we chose potential confounders and dichotomized their cutoff levels of continuous variables (5,24-30). A propensity score-matching analysis (31,32) was used to build a matched group of patients. The propensity score model was estimated using a logistic regression model. A 1:2 match without replacement was performed using
3. Results

3.1. Patient characteristics

Of the 734 patients, 31 (4.2%) received statins for the treatment of dyslipidemia before surgery. There were no patients that received statin at the recommended daily dosages for ≤ 90 days after surgery. The median statin administration period was 37.2 (32.4 – 51.6) months postoperatively. The background characteristics were compared between patients who received statins (statin group) and patients who did not (non-statint group) (Table 1). The proportions of patients with hepatitis B surface antigen (HBsAg) positivity and hepatitis C virus antibody (HCV Ab) positivity were significantly lower in the statin than non-statint group (HBsAg, 6.5% vs. 22.8%, \( P = 0.032 \); HCV Ab, 19.4% vs. 45.0%, \( P = 0.005 \)). The level of triglyceride was significantly higher in the statin than non-statint group (104 (81-150) vs. 89 (68-122) mg/dL, \( P = 0.030 \)). The preoperative AFP concentration was significantly lower in the statin than non-statint group [3.5 (2.3-8.0) vs. 15.0 (5.0-65.3) ng/mL, \( P < 0.001 \)]. There were no significant differences in age, male/female ratio, proportion of patients with hepatitis B core antibody (HBcAb) positivity, Child-Pugh class/A/B/C, number of tumors, maximum tumor diameter, liver functional parameters, or ICG-R15 between the two groups.

3.2. Surgical, histopathological, and postoperative factors

Surgical, histopathological, and postoperative factors are summarized in Table 2. Red blood cell transfusion were performed more frequently in the statin than non-statin group (16.1% vs. 3.1%, \( P = 0.004 \)). There were no significant differences in the operative time, estimated blood loss, or positive surgical margins between the two groups. With respect to histopathological factors, the proportion of patients with a fibrosis score of F3-4 was significantly lower in the statin than non-statin group (16.1% vs. 39.8%, \( P = 0.008 \)). The proportions of tumor differentiation (poor) and major/minor vascular invasion were similar between the groups. The operative mortality rate was 0.0% in the statin group and 0.3% in the non-statint group (\( P > 0.999 \)). The morbidity and major complication rates were similar between the groups. The postoperative hospital stay was significantly shorter in the statin than non-statint group [13 (10-16) days vs. 15 (12-19) days, \( P = 0.022 \)].

3.3. Patient survival

The median follow-up time was 37.2 (32.4-51.6) months in the statin group and 31.2 (16.8-67.2) months in the non-statint group, demonstrating no significant difference (\( P = 0.598 \)). The RFS rate was significantly higher in the statin than non-statint group (\( P < 0.001 \)); the 1-, 3-, and 5- year RFS rates were 87.1%, 76.7%, and 76.7%, respectively, in the statin group, and 65.3%, 40.6%, and 32.9%, respectively, in the non-statint group (Figure 1). The OS rate was not significantly different between the groups: the 1-, 3-, and 5- year OS rates were 96.7%, 89.0 (76.3 - 100), \( P = 0.030 \).
93.1%, and 85.3%, respectively, in the statin group, and 94.2%, 87.1%, and 70.2%, respectively, in the non-statin group (P = 0.142).

3.4. Factors associated with recurrence and overall survival

HCV Ab positivity, use of statins, an ICG-R15 of > 15%, a concentration of > 40 IU/L, an AFP concentration of > 20 ng/mL, a DCP concentration of > 40 mAU/mL, multiple tumors, tumor size of > 2 cm, and vascular invasion were found to be factors that potentially influenced RFS (Table 3). The multivariable Cox proportional hazards model revealed that use of statins (HR, 0.34; 95% CI, 0.12-0.75; P = 0.005) was associated with a significantly lower risk of HCC recurrence. Additionally, an ICG-R15 of > 15% (HR, 1.27), ALT concentration of > 40 IU/L (HR, 1.46), AFP concentration of > 20 ng/mL (HR, 1.39), DCP concentration of > 40 mAU/mL (HR, 1.34), multiple tumors (HR, 1.94), tumor size of > 2 cm (HR, 1.38), and vascular invasion (HR, 1.22) were independent risk factors for RFS. Use of statins was not a significant risk factor for OS (HR, 0.44; 95% CI, 0.11-1.15; P = 0.102) (Table 4). HCV Ab positivity (HR, 1.55), an ICG-R15 of > 15% (HR, 1.39), AFP concentration of > 20 ng/mL (HR, 1.37), multiple tumors (HR, 2.22), tumor size of > 2 cm (HR, 1.72), poor tumor differentiation (HR, 1.79), and vascular invasion (HR, 1.47) were independent risk factors for OS.

3.5. Patient survival evaluation using propensity score-matching analysis

After 1:2 case propensity score matching, 31 patients in the statin group and 62 patients in the non-statin group were analyzed. Patient demographics, and surgical, histopathological, and postoperative outcomes were comparable after the matching (Supplementary Tables S1 and S2, http://www.biosciencetrends.com/action/getSupplementalData.php?ID=15). The RFS rate was significantly higher in the statin than non-statin group (P = 0.008) (Figure 2). The OS rate was not significantly different between the groups (P = 0.581).

4. Discussion

In the present study, the use of statins was significantly associated with a lower HCC recurrence rate. This finding is consistent with the RFS rates in the cohort after excluding patients with hepatitis B and C. The
multivariable analysis revealed that the use of statins reduced the risk of HCC recurrence after initial liver resection.

Certain drugs, including statins, metformin, and aspirins/NSAIDs, have been reported to alter the risk of HCC development (11,13,15-17). One previous study revealed a protective effect of statin use after liver resection (17). The study demonstrated that in patients with hepatitis B virus-related HCC, the use of nucleoside analogues after liver resection was associated with a significantly lower risk of HCC recurrence. Additionally, use of statins (HR, 0.68) and NSAIDS or aspirins (HR, 0.80) were found to be significantly associated with a lower risk of hepatitis B virus-related HCC recurrence. In the present study, use of statins was an independent factor associated with a 0.32-fold lower risk of HCC recurrence in patients including all etiological backgrounds, whereas an ICG-R15 of > 15%, preoperative ALT concentration of > 40 IU/L, preoperative AFP concentration of > 20 ng/mL, preoperative DCP concentration of > 40 mAU/mL, multiple tumors, tumor size of > 2 cm, and vascular invasion were found to be independent risk factors for HCC recurrence.

The underlying mechanism of the protective effect of statins against the development of HCC has not been fully explained. Some possible mechanisms of the protective effects of statins include the suppression of increased inflammation as well as the reduction of fibrosis and proliferation of liver cells. A previous study revealed a protective effect of statin use after liver resection (22). In the present study, use of statins was an independent factor associated with a 0.32-fold lower risk of HCC recurrence in patients including all etiological backgrounds, whereas an ICG-R15 of > 15%, preoperative ALT concentration of > 40 IU/L, preoperative AFP concentration of > 20 ng/mL, preoperative DCP concentration of > 40 mAU/mL, multiple tumors, tumor size of > 2 cm, and vascular invasion were found to be independent risk factors for HCC recurrence.

The underlying mechanism of the protective effect of statins against the development of HCC has not been fully explained. Some possible mechanisms of

Table 3. Cox proportional hazards model analysis for recurrence free survival

<table>
<thead>
<tr>
<th>Variables</th>
<th>Univariable Analysis</th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>HR</td>
<td>95% CI</td>
<td>P value</td>
<td>HR</td>
<td>95% CI</td>
</tr>
<tr>
<td>Age &gt; 65 years</td>
<td>0.92</td>
<td>0.76 - 1.12</td>
<td>0.414</td>
<td>1.05</td>
<td>0.85 - 1.30</td>
</tr>
<tr>
<td>Male</td>
<td>0.86</td>
<td>0.69 - 1.08</td>
<td>0.186</td>
<td></td>
<td></td>
</tr>
<tr>
<td>HBsAg positive</td>
<td>1.06</td>
<td>0.84 - 1.34</td>
<td>0.603</td>
<td>1.05</td>
<td>0.85 - 1.30</td>
</tr>
<tr>
<td>HCCVab positive</td>
<td>0.98</td>
<td>0.80 - 1.20</td>
<td>0.866</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fibrosis (F3-4) vs. (F0-2)</td>
<td>1.20</td>
<td>0.99 - 1.46</td>
<td>0.062</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Use of statin</td>
<td>1.34</td>
<td>1.10 - 1.64</td>
<td>0.004</td>
<td>1.37</td>
<td>1.02 - 1.58</td>
</tr>
<tr>
<td>ALT &gt; 40 IU/L</td>
<td>1.57</td>
<td>1.28 - 1.91</td>
<td>&lt; 0.001</td>
<td>1.46</td>
<td>1.18 - 1.80</td>
</tr>
<tr>
<td>AFP &gt; 20 ng/mL</td>
<td>1.66</td>
<td>1.37 - 2.02</td>
<td>&lt; 0.001</td>
<td>1.39</td>
<td>1.14 - 1.70</td>
</tr>
<tr>
<td>DCP &gt; 40 mAU/mL</td>
<td>1.39</td>
<td>1.14 - 1.71</td>
<td>0.001</td>
<td>1.34</td>
<td>1.07 - 1.68</td>
</tr>
<tr>
<td>Red blood cell transfusion</td>
<td>0.84</td>
<td>0.40 - 1.53</td>
<td>0.592</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Surgical margin, positive</td>
<td>1.62</td>
<td>0.80 - 2.87</td>
<td>0.165</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Multiple tumor vs. solitary tumor</td>
<td>1.97</td>
<td>1.61 - 2.40</td>
<td>&lt; 0.001</td>
<td>1.94</td>
<td>1.58 - 2.38</td>
</tr>
<tr>
<td>Tumor differentiation, poor</td>
<td>1.18</td>
<td>0.81 - 1.66</td>
<td>0.384</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Vascular invasion, positive</td>
<td>1.31</td>
<td>1.07 - 1.60</td>
<td>0.008</td>
<td>1.22</td>
<td>0.99 - 1.49</td>
</tr>
</tbody>
</table>

Abbreviations: HBCab, hepatitis B core antibody; HVCab, hepatitis C virus antibody; ICG-R15, Indocyanine green retention rate at 15 minutes; ALT, alanine aminotransferase; AFP, α-fetoprotein; DCP, des-γ-carboxyprothrombin.

Table 4. Cox proportional hazards model analysis for overall survival

<table>
<thead>
<tr>
<th>Variables</th>
<th>Univariable Analysis</th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>HR</td>
<td>95% CI</td>
<td>P value</td>
<td>HR</td>
<td>95% CI</td>
</tr>
<tr>
<td>Age &gt; 65 years</td>
<td>1.21</td>
<td>0.90 - 1.64</td>
<td>0.213</td>
<td>0.80</td>
<td>0.49 - 1.25</td>
</tr>
<tr>
<td>Male</td>
<td>0.80</td>
<td>0.58 - 1.09</td>
<td>0.152</td>
<td></td>
<td></td>
</tr>
<tr>
<td>HBsAg positive</td>
<td>0.69</td>
<td>0.46 - 1.00</td>
<td>0.049</td>
<td>1.55</td>
<td>1.08 - 2.24</td>
</tr>
<tr>
<td>HCCVab positive</td>
<td>0.98</td>
<td>0.80 - 1.20</td>
<td>0.866</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fibrosis (F3-4) vs. (F0-2)</td>
<td>1.13</td>
<td>0.84 - 1.52</td>
<td>0.417</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Use of statin</td>
<td>0.44</td>
<td>0.11 - 1.15</td>
<td>0.102</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ALT &gt; 40 IU/L</td>
<td>1.65</td>
<td>1.21 - 2.18</td>
<td>&lt; 0.001</td>
<td>1.39</td>
<td>1.01 - 1.92</td>
</tr>
<tr>
<td>AFP &gt; 20 ng/mL</td>
<td>1.54</td>
<td>1.15 - 2.07</td>
<td>0.005</td>
<td>1.35</td>
<td>0.98 - 1.86</td>
</tr>
<tr>
<td>DCP &gt; 40 mAU/mL</td>
<td>1.76</td>
<td>1.31 - 2.36</td>
<td>&lt; 0.001</td>
<td>1.37</td>
<td>1.00 - 1.87</td>
</tr>
<tr>
<td>Red blood cell transfusion</td>
<td>1.94</td>
<td>0.76 - 4.03</td>
<td>0.152</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Surgical margin, positive</td>
<td>2.69</td>
<td>0.95 - 5.95</td>
<td>0.061</td>
<td>1.80</td>
<td>0.54 - 4.50</td>
</tr>
<tr>
<td>Multiple tumor vs. solitary tumor</td>
<td>2.24</td>
<td>1.66 - 3.00</td>
<td>&lt; 0.001</td>
<td>2.22</td>
<td>1.64 - 3.01</td>
</tr>
<tr>
<td>Tumor size &gt; 2 cm</td>
<td>1.50</td>
<td>1.01 - 2.31</td>
<td>0.042</td>
<td>1.72</td>
<td>1.15 - 2.66</td>
</tr>
<tr>
<td>Tumor differentiation, poor</td>
<td>1.62</td>
<td>0.99 - 2.52</td>
<td>0.055</td>
<td>1.79</td>
<td>1.04 - 2.93</td>
</tr>
<tr>
<td>Vascular invasion, positive</td>
<td>1.51</td>
<td>1.12 - 2.02</td>
<td>0.007</td>
<td>1.47</td>
<td>1.08 - 2.00</td>
</tr>
</tbody>
</table>

Abbreviations: HBCab, hepatitis B core antibody; HVCab, hepatitis C virus antibody; ICG-R15, Indocyanine green retention rate at 15 minutes; ALT, alanine aminotransferase; AFP, α-fetoprotein; DCP, des-γ-carboxyprothrombin.

†Based on the classification by Desmet et al. (22). *vs. well/moderate, based on modification of the Edmondson grade (21).
the anticancer effect of statins include inhibition of downstream products of the mevalonate pathway (33,34), triggering of tumor apoptosis (35), inhibition of the proteasome pathway (36), and induction of autophagy (37). Approximately half of patients develop HCC recurrence 3 years after liver resection (2-6). Although adjuvant therapies for HCC have been investigated (7), an effective therapeutic option has not yet been established. Prospective randomized trials are needed to confirm the influence of statin use on patients who have undergone liver resection for HCC.

The main limitation of our study is its retrospective nature and the fact that not all confounders could be completely adjusted for despite the use of a multivariable analysis and a propensity score-matching analysis. The proportion of patients who received statins in our series was small (4.2%); however, this is in line with the limited proportion of patients who underwent liver resection and received statins (3.8%) in a previous report (17). Additionally, the influence of statins was unclear according to each statin type based on the results and the previous studies (11,13,15-17). Second, the protective effects of statins against the development of HCC are not well defined. Additionally, the adverse effects of statins are unclear when they are used for patients without dyslipidemia. Statins are generally contraindicated for patients with liver damage. Finally, we dichotomized continuous variables of potential confounders for HCC prognosis based on previous reports and conducted a multivariable analysis. Such dichotomization may have resulted in lower statistical power.

In conclusion, the risk of HCC recurrence after initial liver resection was lower in patients who received statins than those who did not. Statins may have protective influences on HCC recurrence in patients who undergo initial liver resection, although further studies are needed to elucidate their adverse effects and influences on HCC recurrence.

Acknowledgements

This work was supported by by the Program on the Innovative Development and the Application of New Drugs for Hepatitis B from Japan Agency for Medical Research and Development, AMED (to N.K. and K.M.)

References

acetylsalicylic acid, after the completion of a randomized, placebo-controlled trial. J Gastroenterol. 2015; 50:667-674.

(Received August 20, 2017; Revised October 17, 2017; Accepted October 18, 2017)